Gamida Cell Ltd. (GMDA)
After hours:
| Previous close | 1.7500 |
| Open | 1.7500 |
| Bid | 1.7200 x 1000 |
| Ask | 1.8100 x 1300 |
| Day's range | 1.7100 - 1.7600 |
| 52-week range | 1.7100 - 6.8400 |
| Volume | |
| Avg. volume | 730,674 |
| Market cap | 103.774M |
| Beta (5Y monthly) | 1.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
BOSTON, June 13, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY.
- Business Wire
Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
BOSTON, June 10, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces the appointment of Ivan M. Borrello, M.D. to its Board of Directors, effective June 9, 2022. Dr. Borrello is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a renowned physician and author who has made major contributions to better
- Business Wire
Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
BOSTON, June 02, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced completion of the rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.
